Inhibrx

General Information
Business:

 

We are a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. We combine a deep understanding of target biology with innovative protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design highly differentiated therapeutic candidates. Central to these efforts is our proprietary single domain antibody, or sdAb, platform. Our culture empowers data-driven decision making with the aim of eliminating candidate-selection bias in discovery and development. Initially, we are pursuing therapeutic candidates directed to validated targets, where we believe our protein engineering technologies can overcome prior therapeutic limitations.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 80
Founded: 2017
Contact Information
Address 11025 N. Torrey Pines Road, Suite 200, La Jolla, CA 92037, US
Phone Number (858) 795-4220
Web Address http://www.inhibrx.com
View Prospectus: Inhibrx
Financial Information
Market Cap
Revenues $4.3 mil (last 12 months)
Net Income $-25.7 mil (last 12 months)
IPO Profile
Symbol INBX
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $74.8 mil
Manager / Joint Managers Evercore ISI/ Barclays/ Nomura
CO-Managers Raymond James
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change